These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12814448)

  • 1. Population pharmacokinetics of levosimendan in patients with congestive heart failure.
    Jonsson EN; Antila S; McFadyen L; Lehtonen L; Karlsson MO
    Br J Clin Pharmacol; 2003 Jun; 55(6):544-51. PubMed ID: 12814448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure.
    Sandell EP; Hayha M; Antila S; Heikkinen P; Ottoila P; Lehtonen LA; Pentikainen PJ
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S57-62. PubMed ID: 8907132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
    Harjola VP; Oikarinen L; Toivonen L; Jurkko R; Puttonen J; Sarapohja T; Sundberg S; Nieminen MS
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
    Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
    Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
    Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
    Antila S; Kivikko M; Lehtonen L; Eha J; Heikkilä A; Pohjanjousi P; Pentikäinen PJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery.
    Turanlahti M; Boldt T; Palkama T; Antila S; Lehtonen L; Pesonen E
    Pediatr Crit Care Med; 2004 Sep; 5(5):457-62. PubMed ID: 15329162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
    Antoniades C; Antonopoulos AS; Tousoulis D; Bakogiannis C; Stefanadi E; Stefanadis C
    Curr Drug Metab; 2009 Feb; 10(2):95-103. PubMed ID: 19275545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
    Mebazaa A; Nieminen MS; Filippatos GS; Cleland JG; Salon JE; Thakkar R; Padley RJ; Huang B; Cohen-Solal A
    Eur J Heart Fail; 2009 Mar; 11(3):304-11. PubMed ID: 19158152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan for heart-operated patients: what is the state of the art?
    Tagarakis GI; Tsilimingas NB
    Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):22-4. PubMed ID: 19149702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of levosimendan.
    Antila S; Sundberg S; Lehtonen LA
    Clin Pharmacokinet; 2007; 46(7):535-52. PubMed ID: 17596101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
    Antila S; Honkanen T; Lehtonen L; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan.
    Figgitt DP; Gillies PS; Goa KL
    Drugs; 2001; 61(5):613-27; discussion 628-9. PubMed ID: 11368286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we believe in levosimendan?
    Follath F
    Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial.
    Altenberger J; Parissis JT; Costard-Jaeckle A; Winter A; Ebner C; Karavidas A; Sihorsch K; Avgeropoulou E; Weber T; Dimopoulos L; Ulmer H; Poelzl G
    Eur J Heart Fail; 2014 Aug; 16(8):898-906. PubMed ID: 24920349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.